



## MROQC Bone Mets Project: Clinical Tip Sheet

### Bone Mets Eligibility Criteria

#### **Inclusion Criteria:**

- Patients 18 years and older
- Patients with metastatic breast, non-small cell & small cell lung cancers, prostate, melanoma or renal cell cancer, involving bone, to be treated with external beam radiation to a bony site.

#### **Exclusion Criteria:**

- Bone metastasis is within the treatment field for the primary tumor
- Metastatic disease not involving bone
- Patients who received Xofigo® (Radium Ra-223) within 4 weeks before the start of treatment
- Patients who received Metastron® (Strontium-89) within 4 weeks before the start of treatment
- Patients who received Quadramet® (Samarium-153) within 4 weeks before the start of treatment
- Patients who received Pluvicto® (Lutetium-177) within 4 weeks before the start of treatment

| Bone Mets Cancer                          | MROQC Eligibility |
|-------------------------------------------|-------------------|
| IMPT (Intensity-Modulated Proton Therapy) | Included          |

#### Data Collection Timepoints

| Time Points | Pre-Treatment |
|-------------|---------------|
| Patient     | M6            |
| CDA         | M1, M3        |
| Provider    | M4            |

#### Project Upgrade Dates

| Version # | Upgrade Date    |
|-----------|-----------------|
| V1        | March 19, 2018  |
| V1 → V2   | March 5, 2019   |
| V2 → V3   | January 6, 2021 |

### Reminders

- **Criteria for a new course:** Complete a new set of forms for each new course of treatment. A new course is triggered when there is a gap of 14 or more days between the last fraction of one course and the first fraction of the next. If the treatment dates overlap, or the gap is less than 14 days, complete one set of forms.
- **Multiple courses / Re-irradiation:** "Multiple courses" is the general term for a patient returning for any repeat treatment, regardless of body site. "Re-irradiation" refers specifically to repeat treatment of the same anatomical site.
- **Site reports Bone Mets Tx Start Date Check:** Please check weekly for errors. Patients on these reports will not be counted as eligible for the performance measure until the treatment date error is corrected.
- CDA forms MUST be completed. If a provider form is not completed, please attempt to answer the questions that can be found in the medical record or treatment plan.
- Please use email surveys for patient pre-treatment forms follow-up forms as a priority over paper forms, if possible.
- On May 3rd, 2021 – sites are to enroll only ELIGIBLE patients into the database.

### Project Changes

- **8/26/26:** Multiple-course rule revised: a patient is considered to have started a new course of treatment when there is a gap of 14 or more days between the last fraction of one course and the first fraction of the next. Once this threshold is met, the patient has multiple courses.
- **8/26/26:** Radiopharmaceutical exclusion updated: patients are now excluded only if they received the agent within the 4 weeks before the start of treatment (previously  $\pm$  4 weeks).
- **6/24/25:** New Exclusion criteria added - Bone metastasis is within the treatment field for the primary tumor. SE1 exclusion updated, M4 form distinct bony region updated to reflect new exclusion. M4 systemic therapy question also updated to include – (if yes, answer 9a. and 9b.)



## MROQC Bone Mets Project: Clinical Tip Sheet

- **3/7/25:** M6- Email version discontinued. SE1 – Pluvicto exclusion added, M1 - removed Q4 & 5, M4 – removed Q9, 10, some toxicity scoring symptoms, and changed responses to Q2, M6 - Re-ordered questions.
- **12/12/24:** Cord compression question moved from the M1 to the M4 form - (now a 3 part question)
- **10/6/23:** M2 form removed from bone mets database. Opioids use question added to M1 form.
- **12/9/22:** Cannabis questions updated on the M6 patient form & email survey
- **6/16/22:** New cannabis questions added to the M6 form.
- **10/8/21:** follow-up surveys (M5, M7 and M8) removed from the bone mets database.
- **Starting 7/31/21** follow-up data will no longer be collected on bone mets patients.
- **V3 Upgrade 1/6/21:** updated forms M1, M4 M5, M6, M7 (more information under the 2020 CDA team meeting section on the website- V3 Bone Mets Training).
- **V3 Upgrade 1/6/21:** Patient email surveys (in addition to paper surveys). Sites may choose which method they prefer; however, we strongly recommend email survey. Please do not complete both.

### ECOG → KPS Conversion Table

| PERFORMANCE STATUS CRITERIA |                                                                                                                                                           |           |                                                                                |
|-----------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|--------------------------------------------------------------------------------|
| ECOG (Zubrod)               |                                                                                                                                                           | Karnofsky |                                                                                |
| Score                       | Description                                                                                                                                               | Score     | Description                                                                    |
| 0                           | Fully active, able to carry on all pre-disease performance without restriction.                                                                           | 100       | Normal, no complaints, no evidence of disease.                                 |
|                             |                                                                                                                                                           | 90        | Able to carry on normal activity, minor signs or symptoms of disease.          |
| 1                           | Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light housework, office work. | 80        | Normal activity with effort, some signs or symptoms of disease.                |
|                             |                                                                                                                                                           | 70        | Cares for self, unable to carry on normal activity or do active work.          |
| 2                           | Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours.                           | 60        | Requires occasional assistance, but is able to care for most of his/her needs. |
|                             |                                                                                                                                                           | 50        | Requires considerable assistance and frequent medical care.                    |
| 3                           | Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours.                                                                 | 40        | Disabled, requires special care and assistance.                                |
|                             |                                                                                                                                                           | 30        | Severely disabled, hospitalization indicated. Death not imminent.              |
| 4                           | Completely disabled. Cannot carry on any selfcare. Totally confined to a bed or chair.                                                                    | 20        | Very sick, hospitalization indicated. Death not imminent.                      |
|                             |                                                                                                                                                           | 10        | Moribund, fatal processes progressing rapidly.                                 |
| 5                           | Dead                                                                                                                                                      | 0         | Dead                                                                           |